nano-cannabidiol

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• anxiety [Insufficient Evidence]
• aphthous ulcer (canker sores) [Insufficient Evidence]
• athletic performance [Insufficient Evidence]
• atopic dermatitis (eczema) [Insufficient Evidence]
• bipolar disorder [Insufficient Evidence]
• cachexia, cancer-related [Insufficient Evidence]
• cannabis use disorder [Insufficient Evidence]
• cocaine dependence [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• Crohn dz [Insufficient Evidence]
• dementia [Insufficient Evidence]
• diabetes mellitus, type 2 [Insufficient Evidence]
• dyspepsia [Insufficient Evidence]
• dystonia [Insufficient Evidence]
• epilepsy [Likely Effective]
• essential tremor [Insufficient Evidence]
• exercise-induced muscle damage [Insufficient Evidence]
• exercise-induced muscle soreness [Insufficient Evidence]
• fatigue, cancer-related [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• fragile X syndrome [Insufficient Evidence]
• gastroparesis [Insufficient Evidence]
• graft-versus-host dz [Insufficient Evidence]
• HTN [Insufficient Evidence]
• Huntington dz [Insufficient Evidence]
• IBS [Insufficient Evidence]
• insomnia [Insufficient Evidence]
• multiple sclerosis [Insufficient Evidence]
• nausea/vomiting, chemo-induced [Insufficient Evidence]
• nephrolithiasis [Insufficient Evidence]
• neuropathic pain [Insufficient Evidence]
• obesity [Insufficient Evidence]
• opioid withdrawal [Insufficient Evidence]
• osteoarthritis [Insufficient Evidence]
• pain, acute [Insufficient Evidence]
• pain, cancer-related [Insufficient Evidence]
• pain, chronic [Insufficient Evidence]
• pain, postop [Insufficient Evidence]
• peripheral neuropathy [Insufficient Evidence]
• post-traumatic stress disorder [Insufficient Evidence]
• psoriatic arthritis [Insufficient Evidence]
• psychological well-being [Insufficient Evidence]
• psychosis, acute [Insufficient Evidence]
• psychosis, Parkinson dz-assoc. [Insufficient Evidence]
• rapid eye movement sleep behavior disorder [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• smoking cessation [Insufficient Evidence]
• social anxiety disorder [Insufficient Evidence]
• taste changes, chemo-related [Insufficient Evidence]
• temporomandibular disorder [Insufficient Evidence]